19.84 0.00 (0.00%)
After hours: 4:48PM EDT
|Bid||19.81 x 800|
|Ask||19.86 x 1800|
|Day's Range||18.97 - 19.86|
|52 Week Range||12.19 - 24.30|
|Beta (3Y Monthly)||2.46|
|PE Ratio (TTM)||N/A|
|Earnings Date||Aug 3, 2017 - Aug 7, 2017|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||31.60|
Medical marijuana and recreational marijuana are two high growth sectors in the cannabis industry. Learn about how the two differ, and how you can get into the market.
The cannabis industry has grown in recent months and years, and many companies in the cannabis and health-related industries have been uplisted to reputable U.S. exchanges. Learn about the marijuana stocks on the Nasdaq.
The company reported that dialysis patients experiencing itchiness who were given its Korsuva injection showed statistically significant improvement compared with those on placebo.
STAMFORD, Conn., May 31, 2019 -- Cara Therapeutics, Inc. (Nasdaq: CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities with a.
Cara (CARA) reports positive top-line data from phase III study of Korsuva injection in hemodialysis patients with moderate-to-severe chronic kidney disease-related pruritus.
surged Wednesday after the biopharmaceutical company reported positive results for a Phase 3 trial of a clinical study for its medication, Korsuva, an injection for patients with kidney disease-related itchiness. The Stamford, Connecticut-based company said that dialysis patients experiencing itchiness who were given a Korsuva injection showed statistically significant improvement compared with those on placebo. Chronic kidney disease-associated pruritus (CKD-aP) is is an intractable systemic itch condition that occurs with high frequency and intensity in patients undergoing hemodialysis and peritoneal dialysis, Cara Therapeutics said.
Canada Goose GOOS-CA — Canada Goose shares plummeted more than 30% after the company issued disappointing full-year revenue guidance . Capri Holdings CPRI — The parent company of Michael Kors fell more than 9% after issuing fiscal first-quarter guidance that disappointed investors. Capri said it expects fiscal first-quarter earnings to range between 85 and 90 cents per share.
Small-cap biotech Cara Therapeutics Inc (NASDAQ: CARA ) is trading to its highest level since early April after it released the results of a Phase 3 trial for its lead candidate Korsuva. What Happened ...
The most you can lose on any stock (assuming you don't use leverage) is 100% of your money. But when you pick a...
- Statistically significant improvement in primary endpoint of proportion of patients with three point or greater reduction in mean worst itching intensity NRS score vs. placebo.
If you are looking to invest in cannabis stocks, you may want to take a closer look at cannabis biotechs in particular. Several cannabis biotech firms are generating significant Street support- and for good reason as you will see below. To pinpoint the most compelling cannabis biotech stocks out there, we used TipRanks' data to pull up relevant biotechs with a 'Strong Buy' Street consensus. That's based on all the ratings received from analysts over the last three months. In fact, all these three stocks actually score 100% Street support- so no hold or sell ratings here. Let's take a closer look now at which 3 stocks make the grade, and why: GW Pharmaceuticals (GWPH – Research Report)British-based biopharma GWPH is one of the more well-known cannabis biotech stocks. Shares have put on a remarkable sprint for the beginning of 2019. Year-to-date we are now looking at gains of 88%. And the company’s recent earnings report indicates that plenty of growth lies ahead. In June 2018, the company’s lead cannabinoid drug Epidiolex received FDA approval for the treatment of seizures associated with Lennox-Gastaut syndrome or Dravet syndrome. Following DEA re-scheduling, Epidiolex was launched on November 1.So far the launch has proved a remarkable success. For the first quarter, GW reported $33.5MM in Epidiolex revenue during its first full quarter on the market, well ahead of consensus ($15.9MM). But even more importantly, the company also revealed positive trial data for tuberous sclerosis complex (TSC). Specifically, GW announced that Epidiolex's Phase III trial in patients with seizures associated with tuberous sclerosis complex (TSC) met its primary endpoint with a high degree of statistical significance.The primary endpoint was the percent change from baseline in seizure frequency during the treatment period. At baseline, enrolled patients (average age of 14 years old) experienced a median of 57 seizures per month. After 16 weeks of treatment, patients in the 25 mg/kg/day cohort experienced an impressive 48.6% reduction in seizures relative to baseline.“1Q Snapshot \- A Strong Launch and Positive TSC Data Rolled Into a Joint Announcement for a Double Dose of Good News” cheered JP Morgan’s Cory Kasimov following the report. The analyst continued: “We’re not sure how GWPH’s 1Q19 report could have gone much better with Epidiolex doubling consensus in its first full quarter of sales… only to be one-upped by concurrent positive Phase 3 data in TSC.”As a result he believes Epidiolex is on track to come in north of $150M in its first full year, easily exceeding Street expectations. “The bottom line is that estimates need to come up, perhaps meaningfully. Furthermore, with another positive – and clean – phase 3 dataset in hand, there could be upward bias to longer term off label epilepsy sales, which offers a major upside lever in our model” concludes Kasimov. He reiterated his buy rating while ramping up his price target from $180 to $215. Unsurprisingly, he wasn’t the only analyst singing GWPH’s praises. “Based on Epidiolex's trajectory and the positive TSC data today we are increasing our DCF-based price target from $175 to $200. We continue to think that GW is undervalued” commented Cowen & Co’s Phil Nadeau. At the same time Oppenheimer’s Esther Rajavelu took a step further by upgrading GWPH from Hold to Buy. She also upped her price target from $164 to a Street-high $234 (27% upside). “While we await detailed data that may be shared at a medical conference, we update our probability of approval of the sNDA [supplemental new drug application] for TSC to 87% from 41% (filing expected in 4Q)” she explained. Overall GWPH has a very bullish outlook from the Street, with ten analysts publishing recent buy ratings on the stock. Their average analyst price target stands at $220- indicating upside potential of 20%. View GWPH Price Target & Analyst Ratings Detail Zynerba Pharmaceuticals Inc (ZYNE – Research Report)Zynerba is developing next-generation cannabinoid gels to help treat patients affected by rare neuropsychiatric conditions. The company is generating a significant buzz, with shares exploding over 340% year-to-date! So what’s behind the stock’s meteoric rise?Its lead drug candidate Zygel is a unique permeation-enhanced CBD transdermal gel. By delivering drugs through the skin and directly into the circulatory system, Zygel offers several advantages over oral medication. Most notably, transdermal delivery results in fewer gastrointestinal side effects, and avoidance of first-pass liver metabolism. This potentially enables lower dosage levels of active pharmaceutical ingredients and rapid, reliable absorption. Encouragingly, Zynerba announced earlier this month that the FDA has granted a Fast Track designation on Zygel for the treatment of behavioral problems associated with Fragile X syndrome (FXS). “With this designation, the company gains easier access to the FDA throughout the development process and most importantly, in our view, eligibility for Priority Review, which shortens the review time to six months” explains Ladenburg’s Michael Higgins. He anticipates Zygel’s NDA (new drug application filing) will take place in 1H20, leading to approval in 2H20. And with an eye on the future, Higgins reiterates his buy rating on ZYNE with a $26 price target (97% upside potential). While data since the summer of 2018 has been light, multiple major data readouts are comping up near-term- generating the recent rally in prices. “We continue to believe the stock could still double from its current level, driven by a data-rich 2H’19” the analyst tells investors. Upcoming data readouts include Phase 2 data from BELIEVE 1, evaluating Zygel’s anti-epileptic activity, and data from the FXS pivotal CONNECT-FX trail. “Given the unprecedented, profound and sustained benefits across multiple behavioral problems in the open-label Phase 2 (FAB-C), plus Zygel’s good tolerability, we again expect this trial to be successful” writes Higgins. Plus the catalysts should continue into 1H20 when data is expected for two new indications (autism spectrum disorder (ASD) and 22q11.2 deletion syndrome). Analysts are clearly feeling the heat- this is a stock with five recent back-to-back buy ratings and an average analyst price target of $23 (79% upside potential). View ZYNE Price Target & Analyst Ratings Detail Cara Therapeutics Inc (CARA – Research Report)Cara Therapeutics is a biotech focusing on developing products for better pruritus (i.e. severe itching- one of the most common dermatological complaints) and pain management. Right now, all eyes are squarely set on the imminent US Phase 3 data for IV Korsuva. This is Cara’s novel kappa opioid receptor agonist to treat chronic kidney disease-associated pruritus (CKD-aP) in hemodialysis patients- where there is currently no effective treatment and minimal competitive development.Indeed top-rated Cantor Fitzgerald analyst Charles Duncan has just hosted a call with a key opinion leader (KOL) to discuss the outlook for Korsuva. In this case the KOL is a physician with expertise in chronic kidney disease associated pruritus (CKD-aP), making his insights particularly valuable. Overall, the KOL stated that, in his 25 years as a practicing nephrologist, he has seen little in drug development move the needle in CKD-aP (except the P2 data from KORSUVA), underscoring the need for new medications.“As a result of this recent due diligence, we have enhanced conviction about the P3 study readouts and potential for KORSUVA to usher-in a paradigm shift and a new SoC [standard of care] for this high-burden symptom of disease” Duncan concluded. He expects the data readout to come early June, and is upbeat about the drug's prospects. “We remain confident in positive results based on statistically significant Phase 2b results with much lower powering and shorter treatment duration” the analyst tells investors. Meanwhile, the second global Phase 3, KALM-2, is enrolling and management expects data in “2H19” (i.e. around 4Q). "Assuming KALM-1 is positive, we’ll also be optimistic for KALM-2", says the analyst. He reiterated his buy rating with a $27 price target, writing ‘Now is the time to scratch the itch.’ Given the stock is currently only trading at $18, the price target translates into sizable upside potential of over 50%. Bear in mind shares are already soaring 39% year-to-date. As we can see here, that's on top of six recent buy ratings from the Street:View CARA Price Target & Analyst Ratings Detail Enjoy Research Reports on the Stocks in this Article:Cara Therapeutics Inc (CARA) Research ReportGW Pharmaceuticals (GWPH) Research ReportZynerba Pharmaceuticals Inc (ZYNE) Research Report
Cannabis company Canopy Growth (NYSE:CGC) may have just secured its highest-profile celebrity endorsement yet. Perhaps only topped by the well-publicized relationship between Oprah Winfrey and Weight Watchers (NASDAQ:WW), lifestyle icon Martha Stewart just revealed she invested in an undisclosed stake in Canopy Growth stock because cannabis and cannabinol products are an "alternative to opioids."Source: Shutterstock She's probably not wrong. Insys Therapeutics (NASDAQ:INSY) and Cara Therapeutics (NASDAQ:CARA) are just a couple of several pharmaceutical companies developing ways to use the unique properties of the plant to make effective but not addictive pain-killers.Still, some industry experts are skeptical, and even if the CBD is the basis for an alternative to opioids the world hopes it will be, Canopy Growth role in that sliver of the cannabis movement is modest, at best. Its rise to prominence has been almost entirely driven by recreational use.InvestorPlace - Stock Market News, Stock Advice & Trading TipsTake a closer look at the company though, and you'll find a handful of the (too many) different entities Canopy Growth owns are actually taking aim at the opioid epidemic. * 7 Safe Stocks to Buy for Anxious Investors Pain Relief and Canopy Growth StockThe 77-year Stewart is as in-touch with societal trends as any millennial is, recently explaining of her investment in Canopy Growth stock to Create & Cultivate's founder Jaclyn Johnson, "Well, it's the modern thing, and it's an alternative to opioids of course."It is indeed the modern thing to do. More than 60% of Americans now favor legalizing marijuana, and cannabis has promise as a strong pain reliever.The former model and TV show host went on to undermine her case, however, adding, "I have a lot of animals, and I would love to be able to relieve stress or arthritis or other kinds of problems that my horses, my dogs, my cats experience. We're working on that first, and we're working on additions to human food stuffs, and also on cosmetics."To-date, recreational marijuana has been the crux of the story surrounding Canopy Growth. Of its fiscal Q3 sales of 10,102 kilograms, up 334% year-over-year, the vast majority of it was for recreational usage.The company isn't ignoring its potential role as a supplier of cannabis for true medicinal purposes though. Pharma and Canopy Growth StockAs of the latest look, Canopy owns eight diverse brands, including the relatively new Spectrum Therapeutics, which serves as "the company's healthcare professional and patient-facing identity in medical markets in Canada and around the world." While new, the division has still been undersold.Spectrum Therapeutics is a three-branch unit. Canadian consumers are likely most familiar with Spectrum Cannabis, which supplies medical cannabis using a clever-though-not-complicated color-coding system.It's the other two divisions of Spectrum, however, that quietly look and feel more like pharma companies than a means of simply scoring a high.Canopy Health Innovations, for instance, has secured 38 provisional patents in the United States with more on the way. Overseas, it's involved in eleven different drug-development trials.Cannabinoid Compound Company, also referred to as C3, is Europe's largest cannabinoid-based pharmaceuticals company. Granted, that doesn't necessarily mean a whole lot just yet. The company's dronabinol, however, can be "prescribed by doctors in Germany for any type of chronic pain, and for any condition in palliative care."It's a credible start towards becoming the opioid alternative Martha Stewart believes is possible.Adding to that credibility is the fact that the NFL is exploring the use of cannabis as a means of treating players' pains. That follows a partnership forged between the NHL Alumni Association and Canopy Growth earlier this year, to explore cannabinoids as a means of treating post-concussion neurological diseases… an area the NFL should be exploring as well. Looking Ahead for Canopy Growth StockDon't misread the message. An investment in Canopy Growth stock is an investment in many things, but an investment in opioid alternatives is the least of them. And, it could take years for the prescription-based use of cannabis to catch up with Canopy's recreational business. If that's the impact Stewart is betting on, it could be a long and rocky wait.It's still on the radar though. And, with the opioid market expected to be worth roughly $35 billion by 2025, it's a prospect that would certainly make for a solid second-act from the company. Or, maybe a third act, if the United States legalizes marijuana at the federal level. While certainly game-changing, recreational usage can't drive double-digit and triple-digit growth forever.Besides, the bigger the recreational market gets, the more competitive it becomes, and we've already seen the prices of marijuana fall as it becomes increasingly commoditized.Prescription-based products, preferably co-developed with a major partner, could prove to be a key means for Canopy Growth to differentiate itself and establish a longer-lasting, better-defended growth engine. You've just heard very little about the potential opportunity because it's such a long-term one.As of this writing, James Brumley did not hold a position in any of the aforementioned securities. You can learn more about James at his site, jamesbrumley.com, or follow him on Twitter, at @jbrumley. More From InvestorPlace * 4 Top American Penny Pot Stocks (Buy Before June 21) * 7 Safe Stocks to Buy for Anxious Investors * 4 Tech Stocks Looking Vulnerable * Should You Buy, Sell, Or Hold These 7 Hot IPO Stocks? Compare Brokers The post Even with a Pharma Arm, Canopy Growth Stock Is About Recreational Use appeared first on InvestorPlace.
At Insider Monkey, we pore over the filings of nearly 750 top investment firms every quarter, a process we have now completed for the latest reporting period. The data we've gathered as a result gives us access to a wealth of collective knowledge based on these firms' portfolio holdings as of December 31. In this […]
STAMFORD, Conn., May 08, 2019 -- Cara Therapeutics, Inc. (Nasdaq: CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities with a.
Cara (CARA) delivered earnings and revenue surprises of -1.82% and -14.70%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?
The Stamford, Connecticut-based company said it had a loss of 56 cents per share. The results missed Wall Street expectations. The average estimate of six analysts surveyed by Zacks Investment Research ...
– Conference call today at 4:30 p.m. ET – STAMFORD, Conn., May 07, 2019 -- Cara Therapeutics, Inc. (Nasdaq: CARA), a biopharmaceutical company focused on developing and.
Key Cannabis Sector Updates: Price Action and Analyst Ratings(Continued from Prior Part)Cannabis updateLast week, Emerald Health Therapeutics (EMH) closed with losses of 9.4%. The company released its fourth-quarter and full-year 2018 earnings last
Key Cannabis Sector Updates: Price Action and Analyst RatingsCannabis stocksCannabis ETFs traded on a negative note last week. The Horizons Marijuana Life Sciences ETF (HMMJ) fell 1.2%, while the ETFMG Alternate Harvest ETF (MJ) gained 0.33%. The